Related references
Note: Only part of the references are listed.The economic costs to United States hospitals of invasive fungal infections in transplant patients
Joseph Menzin et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2011)
Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States
Aryun Kim et al.
MYCOSES (2011)
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
R. Herbrecht et al.
BONE MARROW TRANSPLANTATION (2010)
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
Dimitrios P. Kontoyiannis et al.
CLINICAL INFECTIOUS DISEASES (2010)
Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis
John W. Baddley et al.
CLINICAL INFECTIOUS DISEASES (2010)
Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2010)
Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients
Joseph Menzin et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups
Kuo B. Tong et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2009)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients
Penelope D. Barnes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality
Arlo Upton et al.
CLINICAL INFECTIOUS DISEASES (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Invasive Aspergillosis - Epidemiology, diagnosis and management in immunocompromised patients
Georg Maschmeyer et al.
DRUGS (2007)
Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000
TE Zaoutis et al.
PEDIATRICS (2006)
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program
J Morgan et al.
MEDICAL MYCOLOGY (2005)
Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients
R Wenzel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence
KH Vandewoude et al.
JOURNAL OF HOSPITAL INFECTION (2004)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
S Ascioglu et al.
CLINICAL INFECTIOUS DISEASES (2002)
Burden of aspergillosis-related hospitalizations in the United States
EJ Dasbach et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
